This is the first time the growth rate surpassed the country's overall export growth.

An increasing number of Chinese pharmaceutical companies, in particular privately-owned firms in coastal areas, are eyeing the international market.

Chinese pharmaceutical companies are seeing more anti-dumping or anti-subsidy cases. The conflicts are spreading to some major exports.

Domestic companies are working to counteract the on-going dumping claims. They understand that they might totally lose the target market if they do not respond.

Global demand for China's pharmaceuticals is strong.

I am cautiously optimistic the stellar growth in the first decade of commercialization will be surpassed in the second. The number of countries and farmers growing biotech crops is expected to grow, particularly in developing countries.